Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“143 HIFs are heterodimeric transcription factors that consist of a constitutively expressed b -subunit and an oxygen-and iron-regulated a -subunit (either HIF-1 a , HIF-2 a , or HIF-3 a ).”
BackgroundCorrection of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Self-citationFerric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 1×
“99,100 These effects may be important not only for CKD-MBD, but also for cardiovascular and mortality outcomes that are strongly associated with excess FGF23, 101 – 103 although the causative role for excess FGF23 per se in cardiovascular disease is still a matter of debate.”
BackgroundSelf-citationToxicity of iron and hydrogen peroxide: the Fenton reaction
Winterbourn, C. C. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03532-x · Cited by 1,415
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 1×
“29,30 Hypoxia-inducible factors (HIFs), which are stabilized by low oxygen (O 2 ) and low iron conditions, contribute to iron homeostasis and erythropoiesis by regulating the production of EPO in the kidney; ferriductase DCYTB and iron transporters FPN and divalent metal transporter 1 (DMT1) in the…”
BackgroundSazawal, S., Black, R. E., Ramsan, M., Chwaya, H. M., Stoltzfus, R. J., Dutta, A., Dhingra, U., Kabole, I., Deb, S., Othman, M. K., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67962-2 · Cited by 981 · cited 1×
“72 Iron may also promote oxidative stress by participating in the Fenton reaction.”
BackgroundHypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology
Semenza, G. L. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02090-1 · Cited by 930
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Self-citationStoffel, N. U., Cercamondi, C. I., Brittenham, G., Zeder, C., Geurts-Moespot, A. J., Swinkels, D. W., Moretti, D., & Zimmermann, M. B. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30182-5 · Cited by 435 · cited 1×
“117 Similar trials should be conducted in patients with CKD (Table 1).”
BackgroundSelf-citationDetection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Self-citationTargeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis
Liu, Q., Davidoff, O., Niss, K., & Haase, V. H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63924 · Cited by 328
Self-citationAnaemia in kidney disease: harnessing hypoxia responses for therapy
Koury, M. J., & Haase, V. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.82 · Cited by 313
Self-citationMechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309 · cited 1×
“188 Although phase 2 and 3 clinical studies have suggested that HIF-PHIs may be ef fi ca-cious in patients with CKD irrespective of baseline C-reactive protein levels (Table 7), 150,157,177,178,189 overtly in fl amed patients were excluded from most trials.”
BackgroundErythroferrone inhibits the induction of hepcidin by BMP6
Arezes, J., Foy, N., McHugh, K., Sawant, A., Quinkert, D., Terraube, V., Brinth, A., Tam, M., LaVallie, E. R., Taylor, S., et al. (2018) · Blood · doi:10.1182/blood-2018-06-857995 · Cited by 277 · cited 1×
“28 During in fl ammation, IL-6 and other in fl ammatory cytokines induce hepcidin transcription directly via a (STAT)-3 binding element in the hepcidin promoter.”
BackgroundComparative risk of anaphylactic reactions associated With intravenous iron products
Wang, C., Graham, D. J., Kane, R. C., Xie, D., Wernecke, M., Levenson, M., MaCurdy, T. E., Houstoun, M., Ryan, Q., Wong, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.15572 · Cited by 219 · cited 2×
“77 Clinical trial data are now accruing to better evaluate the risks of iron administration in patients with CKD (Table 3 78 – 84 ).”
BackgroundHouston, B. L., Hurrie, D., Graham, J., Perija, B., Rimmer, E., Rabbani, R., Bernstein, C. N., Turgeon, A. F., Fergusson, D. A., Houston, D. S., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019240 · Cited by 159
Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772715 · Cited by 145 · cited 1×
“70,71 The level of labile plasma iron, a component of non – transferrin-bound iron, may also be indicative of impending, clinically signi fi - cant iron overload.”
BackgroundSelf-citationWong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz091 · Cited by 140
Self-citationStoffel, N. U., Uyoga, M. A., Mutuku, F. M., Frost, J. N., Mwasi, E., Paganini, D., van der Klis, F. R. M., Malhotra, I. J., LaBeaud, A. D., Ricci, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01313 · Cited by 112
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0134 · Cited by 97
Volke, M., Gale, D. P., Maegdefrau, U., Schley, G., Klanke, B., Bosserhoff, A.-K., Maxwell, P. H., Eckardt, K.-U., & Warnecke, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007875 · Cited by 93 · cited 1×
“Instead, systemic or liver-speci fi c HIF activation suppresses hepcidin indirectly through EPO-dependent effects on erythropoiesis, 174 – 176 which is the same mechanism of action for hepcidin suppression by traditional ESAs.”
BackgroundSelf-citationStefanova, D., Raychev, A., Deville, J., Humphries, R., Campeau, S., Ruchala, P., Nemeth, E., Ganz, T., & Bulut, Y. (2018) · Infection and Immunity · doi:10.1128/iai.00253-18 · Cited by 68
Self-citation
Cited by
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Self-citationHaase, V. H., Tanaka, T., & Koury, M. J. (2024) · Hematology · doi:10.1182/hematology.2024000655 · Cited by 19
Self-citation
Metadata
- Authors
- Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Małyszko, J., Swinkels, D. W., Tarng, D.-C., Cheung, M., Jadoul, M., Winkelmayer, W. C., Drüeke, T. B., Abu-Alfa, A. K., Afsar, B., Pai, A. B., Besarab, A., Moore, G. B., Casadevall, N., Cases, A., de Francisco, A., Eckardt, K.-U., Fishbane, S., Fried, L. F., Ganz, T., Ginzburg, Y. Z., Gómez, R., Goodnough, L. T., Hamano, T., Hanudel, M. R., Hao, C.-M., Iseki, K., Ix, J. H., Johansen, K. L., Ketteler, M., Kovesdy, C. P., Leaf, D. E., Macdougall, I. C., Massy, Z. A., McMahon, L. P., Minutolo, R., Nakanishi, T., Nemeth, E., Obrador, G. T., Parfrey, P. S., Park, H.-C., Pecoits-Filho, R., Robinson, B. M., Roger, S. D., Shah, Y. M., Spinowitz, B. S., Tanaka, T., Tsukamoto, Y., Tungsanga, K., Walther, C. P., Yee-Moon Wang, A., & Wolf, M.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 99
- Issue
- 6
- Pages
- 1280-1295
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3144773245
- Cited by
- 215
- References
- 25
- FWCI
- 21.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.